Olaparib Monotherapy for Previously Treated Pancreatic Cancer With DNA Damage Repair Genetic Alterations Other Than Germline BRCA Variants-Reference-Cited by-同舟云学术

Olaparib Monotherapy for Previously Treated Pancreatic Cancer With DNA Damage Repair Genetic Alterations Other Than Germline BRCA Variants

Published:2021-05-01 Issue:5 Volume:7 Page:693
ISSN:2374-2437
Container-title:JAMA Oncology
language:en
Short-container-title:JAMA Oncol

Author:

Javle Milind¹,Shacham-Shmueli Einat²,Xiao Lianchun³,Varadhachary Gauri¹,Halpern Naama²,Fogelman David¹,Boursi Ben²,Uruba Syeda¹,Margalit Ofer²,Wolff Robert A.¹,Golan Talia²

Affiliation:

1. Department of Gastrointestinal Medical Oncology, MD Anderson Cancer Center, Houston, Texas

2. Oncology Institute, Sheba Medical Center, Tel Hashomer, Israel

3. Department of Biostatistics, MD Anderson Cancer Center, Houston, Texas

Publisher

American Medical Association (AMA)

Subject

Oncology,Cancer Research

Link

https://jamanetwork.com/journals/jamaoncology/articlepdf/2776814/jamaoncology_javle_2021_oi_210001_1621005002.69732.pdf

Reference20 articles.

1. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation.;Kaufman;J Clin Oncol,2015

2. Evidence for the efficacy of Iniparib, a PARP-1 inhibitor, in BRCA2-associated pancreatic cancer.;Fogelman;Anticancer Res,2011

3. Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer.;Golan;N Engl J Med,2019

4. Molecular profiling of patients with pancreatic cancer: initial results from the Know Your Tumor Initiative.;Pishvaian;Clin Cancer Res,2018

Cited by 68 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. NLRP4 renders pancreatic cancer resistant to olaparib through promotion of the DNA damage response and ROS-induced autophagy;Cell Death & Disease;2024-08-26

2. Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with biliary tract cancer;ESMO Open;2024-08

3. The efficacy and safety of PARP inhibitors in mCRPC with HRR mutation in second-line treatment: a systematic review and bayesian network meta-analysis;BMC Cancer;2024-06-08

4. Variants of uncertain significance in precision oncology: nuance or nuisance?;The Oncologist;2024-06-07

5. Zielgerichtete Therapie des Pankreaskarzinoms;Gastro-News;2024-06